According to the study “Myelodysplastic Syndrome – Pipeline Review, H1 2018”, global myelodysplastic syndrome market will witness a growth at a moderate pace due to insufficient medical needs, increasing public awareness, and increase in the aged population. Many leading vendors are capable of manufacturing and marketing drugs that can be effectively treated and used to cure myelodysplastic syndrome. The global leading vendors in myelodysplastic syndrome market are 4SC AG, AbbVie Inc, Acceleron Pharma Inc, Actinium Pharmaceuticals Inc, Aeglea BioTherapeutics Inc., Agios Pharmaceuticals Inc., Aileron Therapeutics Inc., AIMM Therapeutics BV, Altor BioScience Corp, Amgen Inc, Angiocrine Bioscience Inc., Apogenix AG, Aprea AB and others.
Myelodysplastic syndrome (MDS) is a group of hematologic disorders that arises from the human bone marrow and spreads quickly to the blood. Various diagnostic tools and techniques are available in the global market such as blood count, peripheral blood smear test, microscopic exams, cytochemistry, flow cytometry, immunotherapy, cytogenetics, FISH, and PCR that help in detecting myelodysplastic syndrome. These advanced diagnostic tools and techniques have a positive impact on the available myelodysplastic syndrome drugs. The symptoms of early stage of myelodysplastic syndrome are fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.
Myelodysplastic syndrome market is spread across APAC, EMEA and Americas. Americas are dominating the global market for myelodysplastic syndrome over the past few years and will continue over the next few years due to various factors such as insufficient medical needs along with the increase in ageing population. Various segments available in drugs and analysis of the myelodysplastic syndrome market are alkylating agents, cytotoxic antibiotics, topoisomerase inhibitors and others. The available alkylating agents in the global market are used to treat different types of cancer and function by attaching an alkyl group to the guanine base of the human DNA. The various alkylating agents that are used for the treatment of myelodysplastic syndrome are Dacogen by Otsuka and Vidaza by Celgene.
The pipeline review guide on myelodysplastic syndrome provides a comprehensive information on the new therapeutics that are under development, drug target, mechanism of action (MoA), route of administration (RoA), molecule type, descriptive pharmacological action of new therapeutics, complete report on research and development history and latest news or press releases reports. The pipeline guide also provides the emerging players involved in therapeutic development for myelodysplastic syndrome, list of therapeutics under development or rejected in various companies or universities or institutes, clinical trial registries, conferences, SEC filings, investor presentations and industry-specific third party sources. With the availability of advanced technology, various dynamic tracking processes are captured on a real time basis. The guide provides an overview of the myelodysplastic syndrome, global market trends in various countries such as United States, EU5 (France, Germany, Italy, Spain, UK) and Japan, therapeutics market revenue, average cost of therapy, treatment practice, forecast of myelodysplastic syndrome, and global forecast of epidemiology of myelodysplastic syndrome. The global market for myelodysplastic syndrome is expected to grow steadily with the discovery of some novel pipeline molecules, which will results in a steady market growth rate over the next few years.
To know more click on the link below:
Related Report:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
0124-4230204
